Medicenna Therapeutics Company Executives
| MDNA Stock | CAD 1.77 0.10 5.99% |
Medicenna Therapeutics employs about 16 people. The company is managed by 6 executives with a total tenure of roughly 38 years, averaging almost 6.0 years of service per executive, having 2.67 employees per reported executive. Analysis of Medicenna Therapeutics' management performance can provide insight into the firm performance.
Medicenna |
Medicenna Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.328) % which means that it has lost $0.328 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0543) %, meaning that it generated substantial loss on money invested by shareholders. Medicenna Therapeutics' management efficiency ratios could be used to measure how well Medicenna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -1.4. In addition to that, Return On Capital Employed is likely to grow to -1.15. At this time, Medicenna Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 27th of November 2024, Non Current Assets Total is likely to grow to about 87.7 K, while Total Assets are likely to drop about 19 M.As of the 27th of November 2024, Common Stock Shares Outstanding is likely to drop to about 38.4 M. In addition to that, Net Loss is likely to drop to about (9.5 M)
Medicenna Therapeutics Workforce Comparison
Medicenna Therapeutics Corp is regarded second in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 58.0. Medicenna Therapeutics totals roughly 16.0 in number of employees claiming about 28% of equities under Health Care industry.
Medicenna Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medicenna Therapeutics Price Series Summation is a cross summation of Medicenna Therapeutics price series and its benchmark/peer.
Medicenna Therapeutics Notable Stakeholders
A Medicenna Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medicenna Therapeutics often face trade-offs trying to please all of them. Medicenna Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medicenna Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MESc BSc | Founder Officer | Profile | |
| Fahar Merchant | Chairman, Founder | Profile | |
| MBBS MD | Acting Devel | Profile | |
| MD FCAP | Chief Officer | Profile | |
| CBV CA | Chief Officer | Profile | |
| Samuel MD | Scientific Advisor | Profile |
About Medicenna Therapeutics Management Performance
The success or failure of an entity such as Medicenna Therapeutics often depends on how effective the management is. Medicenna Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medicenna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medicenna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.40) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (4.91) | (4.66) |
Medicenna Therapeutics Workforce Analysis
Traditionally, organizations such as Medicenna Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medicenna Therapeutics within its industry.Medicenna Therapeutics Manpower Efficiency
Return on Medicenna Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 4.2M | |
| Working Capital Per Employee | 1M | |
| Working Capital Per Executive | 2.7M |
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.